B · Normal
[AI pharmaceutical company Iambic backed by NVIDIA submits U.S. IPO application] "Science and Technology Innovation Board Daily" reported on the 22nd that Iambic Therapeutics, an AI pharmaceutical company backed by NVIDIA and Qatar's sovereign wealth fund, submitted a U.S. initial public offering (IPO) application on Monday local time. Founded in 2019 (formerly known as Entos), Iambic is currently advancing a pipeline of drug candidates developed using its AI platform to treat solid tumors. Its most advanced drug candidate, IAM1363, is in early-stage clinical trials for the treatment of solid tumors such as breast cancer.
AI 🕐 2026-09-22 08:39
#clinical trial #NVIDIA #AI
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Nvidia’s price-to-earnings ratio has dropped to its lowest level in more than a 09-22 18:49 [Four-connected Nanhua Bio: Cell therapy-related technologies and products are s 09-22 18:20 [Analyst: The moat of personal intelligence far exceeds that of chatbots. OpenAI 09-22 17:56 On September 22, Alibaba’s US stocks rose by more than 3% before the market open 09-22 17:51 [Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subje 09-22 17:43 [Qianwen Office releases "Enterprise Context"] On September 22, according to Ali 09-22 17:29

Comments

0/500
Captcha (click to refresh)
No comments yet